机构看好创新药研发进程加速，港股创新药ETF（159567）早盘一度涨逾2%

Core Viewpoint - The Hong Kong pharmaceutical and biotechnology sector is experiencing a rebound, with the Hong Kong Innovative Drug ETF (159567) showing a significant increase, indicating a potential end to the previous two-day decline [1] Group 1: Market Performance - The Hong Kong Innovative Drug ETF (159567) opened higher and recorded a 2.01% increase by 9:54 AM, with a trading volume exceeding 570 million yuan [1] - Year-to-date, the ETF has risen over 100%, placing it in the top tier of all ETFs in the market [1] - Since September, as of September 17, the ETF's shares have increased by 1.485 billion shares, nearing the total increase of 1.571 billion shares in August, marking eight consecutive months of positive growth [1] Group 2: Institutional Insights - Institutions believe that policy support will significantly accelerate the R&D process for innovative drugs, enabling companies to complete clinical trials more quickly and achieve earlier product launches [1] - Improved R&D efficiency is expected to lower development costs, reduce capital occupation time, and enhance cash flow [1] - With policies aligning towards globally synchronized R&D, innovative drug companies with international capabilities will have more opportunities to conduct international multi-center clinical trials, thereby enhancing their global competitiveness [1] Group 3: ETF Characteristics - The Hong Kong Innovative Drug ETF (159567) tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index, aiming to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [1] - Investors can also access the Hong Kong Innovative Drug ETF through linked funds (Class A: 023929; Class C: 023930) for a streamlined investment in the upward potential of the Hong Kong innovative drug sector [1]